Bot Chart, page-8233

I agree with you that the market is underestimating the opportunity here - but why do you think that is? I don't think it all rests on simply getting FDA or not - maybe a little bit, but not multiple bags. I think the market seems to have largely priced in what we know is almost a certainty. I've often wondered before if it is simply because our supposed primary competition, Qbrexza, only earns something like $25m/yr in this market. But the research conducted shows a market with immediate potential of hundreds of millions. If we simply replicate Japan's performance we should be looking at $100m revenue (which easily prices BOT with a $ sign). Is the market just that fickle in this current state and BOT needs to demonstrate sales first before we get significant SP improvement, or do you think there are other reasons?